TrkB and TrkC are differentially regulated by excitotoxicity during development of the basal ganglia.
During development neurons are protected against various insults by intrinsic properties. Here we evaluate trkB (both full-length and truncated forms) and trkC expression in the striatum, cortex, and substantia nigra after intrastriatal injection of quinolinic acid (QUIN) at different stages of postnatal (P) development, by RNase protection assay and in situ hybridization. During normal development, a region-specific regulation of trkB and trkC was observed, showing the maximal mRNA levels at P5. Excitotoxic lesion did not modify striatal trkB mRNA levels at any age examined. However, trkC decreased after QUIN injection at P5 in the striatum (52 +/- 2% of control levels). On the other hand, regulation of trkB and trkC expression was observed in cortex and substantia nigra after striatal excitotoxic lesion. Both full-length and truncated receptor isoforms of trkB were enhanced in the cortex when striatal injury was produced at P21 (268 +/- 38 and 206 +/- 35%) or P30 (174 +/- 35 and 157 +/- 13%). In situ hybridization studies localized this increase in trkB expression in layers II/III and V along the cerebral cortex. Within the substantia nigra, striatal excitotoxicity at P5 selectively decreased the truncated form of trkB (70 +/- 7%), whereas the full-length form was up-regulated at P30 (130 +/- 2%). A biphasic increase in trkC mRNA levels was observed at P5 (151 +/- 3%) and P21 (168 +/- 4%). These changes were localized in the substantia nigra pars compacta. Triple-labeling studies disclosed that all these changes were mainly located in neurons. These results demonstrate that the endogenous response to excitotoxicity includes transneuronal regulation of neurotrophin receptors, which is specific for each nucleus and depends on the developmental stage.
Checa
N
N
Departament de Biologia Cel. lular i Anatomia Patològica, Facultat de Medicina, Universitat de Barcelona, IDIBAPS, Casanova 143, Barcelona, 08036, Spain.
Canals
J M
JM
Gratacòs
E
E
Alberch
J
J
D000375:Aging / Q000378:metabolism; D000818:Animals; D000831:Animals, Newborn / Q000254:growth & development / Q000378:metabolism; D001479:Basal Ganglia / Q000254:growth & development* / Q000378:metabolism*; D002540:Cerebral Cortex / Q000378:metabolism; D003342:Corpus Striatum / Q000187:drug effects / Q000502:physiology; D007267:Injections; D008297:Male; D009498:Neurotoxins / Q000494:pharmacology*; D017378:Quinolinic Acid / Q000494:pharmacology*; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D020813:Receptor, trkB / Q000235:genetics / Q000378:metabolism*; D020812:Receptor, trkC / Q000235:genetics / Q000378:metabolism*; D013378:Substantia Nigra / Q000378:metabolism
D009498:Neurotoxins; D012333:RNA, Messenger; D020813:Receptor, trkB; D020812:Receptor, trkC; D017378:Quinolinic Acid